News

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process.

Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and other commodities in highly energetically favorable (high yield, high purity) production. Allozymes is optimizing key enzymes in the pathway to meet large-scale production specifications. The collaboration includes Allozymes’ cutting edge microfluidics-based protein engineering platform to achieve what was previously thought impossible: analyzing up to 20 million enzyme variants a day, delivering superior success rates, and dramatically reducing development timelines for novel enzymes.

“Optimizing enzymes for industrial-scale production requires precision, speed, and innovation, and our collaboration with Bonumose exemplifies this,” said Akbar Vahidi, Chief Technology Officer of Allozymes. “By leveraging our microfluidics-based protein engineering platform, we have been able to rapidly enhance key enzymes, significantly improving the process efficiency and scalability. The early results are promising, and we are confident that this partnership will unlock new possibilities in sustainable and cost-effective ingredient production.”

Dr. Daniel Wichelecki, Bonumose’s Chief Scientific Officer and Co-Founder, states, “Our mission is to produce healthy food and supplement ingredients in a low-cost, scalable production process. Our development collaborator Allozymes has shown promising results in the initial phases of our collaboration. We are on track and confident to meet our developmental objectives.”

The companies are pleased with the important milestone in both companies’ agenda of leveraging the use of enzymes to accelerate timelines and meet ambitious targets for producing beneficial ingredients to meet global needs for healthy food, dietary supplements, and other important categories.

“Our goal is to drive the future of sustainable food ingredient production through enzyme innovation,” said Akbar Vahidi. “Our collaboration with Bonumose is a critical part of this mission and we aim to demonstrate a successful model on how Allozymes enables innovation in the food ingredient market. With our unique platform, we are confident that we’ll continue to reduce development timelines and enhance performance, setting a new benchmark in the industry.”

 

Read more here.

Recent News

08/11/2026

Pascal Medical Corporation Secures $3.8M to Advance ClickGel Into Pivotal Large Animal Testing

Pascal Medical Corporation has raised $3.8 million to push its ClickGel surgical sealant through pivotal large animal testing on the way to human trials. The total combines a $3 million private financing round closed in July with an $800,000 grant from Virginia Catalyst, announced by Governor Abigail Spanberger on July 30, 2026. Pascal will use

08/10/2026

Expanding visibility with wearable blood pressure monitoring: CareTaker

In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient

08/10/2026

BIO-CAT Joins the Lallemand Family

BIO-CAT is pleased to join the Lallemand family as we begin an exciting new chapter together. Effective July 31, 2026, Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials. Together, we are combining complementary expertise in enzymes, microbial technologies, fermentation, and life science innovation to create an even stronger platform for developing next-generation